Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials

Abstract Background We sought to identify patient subgroups with distinct postprogression overall survival (ppOS) outcomes and investigate the impact of original treatment assignment and initial postprogression treatment (ppRx) on ppOS. Methods Recursive partitioning analysis (RPA) was performed to...

Full description

Bibliographic Details
Main Authors: Paolo A. Ascierto, Antoni Ribas, James Larkin, Grant A. McArthur, Karl D. Lewis, Axel Hauschild, Keith T. Flaherty, Edward McKenna, Qian Zhu, Yong Mun, Brigitte Dréno
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Journal of Translational Medicine
Subjects:
Vemurafenib
Cobimetinib
Dacarbazine
Melanoma
Survival analysis
Online Access:http://link.springer.com/article/10.1186/s12967-020-02458-x

Internet

http://link.springer.com/article/10.1186/s12967-020-02458-x

Similar Items